Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HER2-positive Breast Cancer × trastuzumab deruxtecan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 20 Neoplasm Metastasis 9 Stomach Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Colorectal Neoplasms 3 Brain Neoplasms 3 Adenocarcinoma 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Neoplasms 2 Meningeal Carcinomatosis 2 Esophageal Neoplasms 2 Breast Cancer With Brain Metastasis 2 Salivary Gland Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neoplasm, Residual 1 HER2-positive Breast Cancer 1 HER2-negative Breast Cancer 1 HER2-mutant Non-Small Cell Lung Cancer 1 HER2-low Hormone Receptor Positive Breast Cancer 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Gastric Adenocarcinoma 1 Carcinoma 1 Breast Cancer Metastatic 1 Advanced Breast Cancer 1

Interventions

Trastuzumab 11 pyrotinib 8 pertuzumab 5 Docetaxel 5 Paclitaxel 2 Carboplatin 2 Capecitabine 2 tucatinib 1 trastuzumab deruxtecan 1 pegfilgrastim 1 neratinib 1 liposomal doxorubicin 1 inavolisib 1 exemestane 1 envafolimab 1 dalpiciclib 1 atezolizumab 1 Neoadjuvant Therapy 1 Metformin 1 Leuprolide 1 Goserelin 1 Fulvestrant 1 Drug Therapy 1 Anastrozole 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05982678 2025-11-26

ANISE

The Netherlands Cancer Institute

Phase 2 Recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡